Full Year 2023 Investor Presentation

10 Investor presentation Full year 2023 Rare disease sales decreased by 15% driven by reduction in manufacturing output Reported Rare disease sales Rare disease sales driven by global commercial execution Growth at CER DKK billion 20 -15% 3% 6% 15 Rare disease sales decrease is driven by: 46% -3% -47% • 1% sales decline in North America Operations • 24% sales decline in International Operations 10 Rare blood disorders 5 0 Total1 Rare blood Haem. A Haem. B Novo- ! SevenⓇ disorders² Rare endocrine disorders³ Novo NordiskⓇ • • Rare blood disorders sales increased by 3%, driven by: Extended half-life products in haemophilia A and B, partially countered by NovoSevenⓇ Rare endocrine disorders sales decreased by 47% driven by: Sales for Norditropin® declined by 26% in NAO and 63% in IO, reflecting a reduction in manufacturing output Novo Nordisk has a value market share of 19.3% in the global human growth disorder market SogroyaⓇ has now been launched in five countries 1Total includes "Other Rare disease", which consists of primarily Vagifem® and ActivelleⓇ: 2Comprises NovoSeven®, Novo Eight®, Esperoct®, Refixia® and NovoThirteenⓇ; 3 Primarily Norditropin® CER: Constant exchange rates; Haem. A: Haemophilia A; Haem. B: Haemophilia B; NAO: North America operations; IO: International operations Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar. Unless otherwise specified, sales growth is at constant exchange rates.

View entire presentation